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BACKGROUND
Norovirus is the leading cause of acute gastroenteritis across all age groups in the United 
States.1 It is also a frequent cause of outbreaks in health care settings, including long-term 
care facilities (LTCFs) and acute care hospitals.2 The total burden of disease is high; 
norovirus is estimated to cause approximately 21 million total illnesses annually across all 
age groups in the United States.1 Certain populations are at higher risk of infection and 
severe illness, including those at the extremes of age. In high-income and upper-middle–
income (HI/UMI) countries, between 2000 and 13,000 norovirus-associated deaths occur in 
older adults greater than 65 years of age.3 Infection with norovirus is also costly to society. 
Annual hospitalization costs in the United States are estimated at $493 million4 and 
outpatient and emergency department visits at $284 million.5 For patients greater than 65 
years of age, total hospitalization costs for norovirus and gastroenteritis are higher compared 
with younger age groups.4 Additionally, all foodborne norovirus illness, including 
productivity losses, are estimated at $2 billion per year in the United States.6 This review 
summarizes knowledge on norovirus infection in older adults.
VIROLOGY AND VIRAL DIVERSITY
The norovirus genome is composed of a linear, positive-sense RNA that is approximately 7.6 
kb in length.7 The 3 open reading frames (ORFs), ORF-1, ORF-2, and ORF-3, encode 8 
viral proteins (VPs); ORF-2 and ORF-3 encode the structural components of the virion, VP1 
and VP2. ORF-1 encodes nonstructural proteins, including the norovirus protease and RNA-
dependent RNA polymerase.8
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Noroviruses belong to the family Caliciviridae and are divided into 7 genogroups based on 
the viral capsid gene. Three of these genogroups, GI, GII, and GIV, include strains that 
infect humans. Noroviruses are classified further into genotypes, and there are at least 21 
genotypes in GII and 8 genotypes in GI.9 Globally, GII.4 viruses are the predominant 
pathogen, include new variants that emerge every 2 to 4 years, and are associated with 
greater symptom severity in the young and elderly, resulting in more hospitalizations and 
deaths.10,11 In the most recent United States norovirus season, from September 1, 2016, to 
April 21, 2017, of 502 samples tested, the predominant strain was GII.P16-GII.4 Sydney, 
accounting for 60% of outbreaks; other strains included GII.2 (14% of outbreaks), GI.3 (7% 
of outbreaks), GII.6 (4% of outbreaks), and GII.Pe-GII.4 Sydney (3% of outbreaks); other 
genotypes accounted for the remaining 12%.12
CLINICAL PRESENTATION AND DISEASE COURSE
After an incubation period of 12 hours to 48 hours,13 the classic symptoms of norovirus 
disease include sudden onset of vomiting, abdominal cramps, and watery diarrhea.14,15 
Constitutional symptoms, including low-grade fever, generalized myalgias, malaise, 
headache, and chills, frequently accompany the gastroenteritis.13 Vomiting and diarrhea are 
usually present together, but either can be seen alone.16 Most patients experience a brief, 
self-limited infection with symptoms resolving within 2 days to 3 days. The clinical 
spectrum of illness is varied, however, and up to one-third of those infected are 
asymptomatic.17 On the other end of the spectrum, the most vulnerable include those with 
underlying medical conditions, the very young, the elderly, and the immunocompromised, 
who are at greater risk for severe symptoms and complications,18 such as acute renal failure 
leading to hemodialysis, cardiac complications including arrhythmias, acute graft organ 
rejection in transplant recipients, and death.19,20
Complications among healthy adults are less common. Transient postinfectious 
inflammatory bowel syndrome has been reported up to 3 months postonset of symptoms 
compared with controls21 as well as long-term sequelae among US military recruits who 
experienced gastroenteritis during norovirus outbreaks, including dyspepsia, constipation, 
and gastrointestinal reflux disease.22 Neurologic symptoms are rare but have been observed. 
Headache, neck stiffness, photophobia, and obtundation were observed together with 
gastrointestinal symptoms in 3 British military personnel; 1 of these patients also had 
disseminated intravascular coagulation, and 2 patients required ventilator support.23 Other 
infrequent complications have been reported among healthy people, including necrotizing 
enterocolitis, seizures, and postinfectious arthritis in the pediatric population24–26 as well as 
individual case reports among adults of ischemic colitis, transient hepatocellular injury, and 
hemolytic uremic syndrome.27–29
Clinical Symptoms and Severity of Norovirus in Older Adults (Greater Than or Equal to 65 
Years of Age)
Older adults form a high-risk group for severe symptoms and clinical outcomes.20 Norovirus 
outbreak investigations have reported a longer duration of diarrhea, from 3 days to 9 days, in 
older adults20,30 and even slower recovery from illness in patients greater than or equal to 85 
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years of age, with almost half of those affected still symptomatic after 4 days.31 Clinical 
symptoms other than diarrhea may also be prolonged in this age group; 1 study reported 
persistent headache, thirst, and vertigo as long as 19 days postonset of illness in 10 
individuals 79 years old to 94 years old in an agedcare facility, although the diarrhea and 
vomiting had resolved by day 4 postonset.30
If they are hospitalized with norovirus infection, older adults are more frequently admitted to 
an ICU.32 Also, compared with younger hospitalized patients, older adults who are 
hospitalized for other conditions are more likely to acquire a nosocomial norovirus infection.
33,34
 This propensity for ICU care–acquired and hospital-acquired infections could be due to 
longer hospital stays and increased exposures, but it could also be secondary to increased 
susceptibility to the virus due to age-related changes in B-cell and T-cell function and 
immunosenescence or underlying chronic conditions and comorbidities.
These age-related factors are also likely contributors to the high mortality rate in this age 
group from norovirus-associated illness.35 It is estimated that a vast majority (90%) of 
norovirus-associated deaths in the United States occur among persons greater than or equal 
to 65 years of age (Fig. 1). In a study of norovirus outbreaks in nursing homes, all-cause 
mortality was higher in outbreak periods compared with nonoutbreak periods.36 When 
norovirus-associated deaths do occur, most infections are acquired in LTCFs and hospitals; a 
global review in developed countries found that immediate causes of death in these scenarios 
included sepsis, aspiration pneumonia, and cardiac complications.37
Prolonged Infection and Complications in the Immunocompromised
Immunocompromised hosts, including those who are immunosuppressed due to congenital 
or acquired immunodeficiencies, transplant, receipt of immunosuppressive therapy, and 
cancer, are at increased risk for prolonged and more severe norovirus illness.38 Several 
studies have demonstrated chronic infection and prolonged shedding of norovirus for months 
to years after solid or liquid organ transplant and prolonged illness in individuals with 
leukemia and lymphoma.39–43 Duration of symptoms and viral excretion in 
immunocompromised hosts has ranged from 6 days to 420 days and 11 days to 420 days in 
hematopoietic stem cell transplant recipients, respectively, and 24 days to 1004 days and 6 
days to 898 days in renal transplant recipients.44 Immunocompromised patients who are 
chronically infected with norovirus potentially transmit the infection to immunocompetent 
adults, although nosocomial outbreaks stemming from immunocompromised patients are 
rare.18
Norovirus infections in renal transplant patients have also been shown to result in more 
severe symptoms compared with gastroenteritis due to bacteria or parasites, including 
greater weight loss, 8.7-fold longer duration of symptoms, more frequent medication 
adjustments, prolonged viral shedding, and post-transplant chronic diarrhea potentially 
complicated by severe kidney graft impairment.40 In some cases, immunosuppressive 
therapy has been temporarily suspended in renal transplant patients because of the severity 
of clinical symptoms, including severe dehydration and cardiovascular instability.20 Further 
complicating the care of norovirus-infected immunocompromised patients is a potential 
delay in diagnosis that can result from overlapping clinical symptoms experienced by 
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oncologic patients undergoing therapy with those typical for acute norovirus infection.41 
Norovirus-associated deaths in patients with varying degrees of immunosuppression have 
been reported37 as well as deaths directly attributable to norovirus in immunocompromised 
patients.18,45
VIRAL SHEDDING AND TRANSMISSION
Norovirus is highly contagious, and the infectious dose can be small (18–2800 viral 
particles).46,47 The most common route for transmission is person to person, either directly 
through the fecal-oral route, by ingestion of aerosolized vomitus, or by indirect exposure via 
fomites or contaminated environmental surfaces.9 Foodborne transmission is also common 
and can occur by contamination from infected food handlers or directly from contaminated 
foods. Foods often implicated in norovirus outbreaks include leafy greens, fresh fruits (such 
as raspberries), and shellfish (such as oysters), but any food that is served raw or handled 
after being cooked can be contaminated.48–52 Waterborne transmission is also possible, 
particularly when drinking or recreational water are not chlorinated. In health care settings, 
the most common mode of transmission is through direct contact with infected persons or 
contaminated equipment.
The characteristics of norovirus shedding also play a role in transmission dynamics, 
although the infectivity of the virus beyond the symptomatic period is not well established.
9,53
 Shedding occurs primarily in stool but can also be present in vomitus. Although peak 
viral shedding occurs 2 days to 5 days after infection,9 viral RNA has been detected in stool 
samples for up to 4 weeks to 8 weeks in otherwise healthy individuals.53 Higher viral loads 
have been reported in symptomatic patients compared with those who have been 
asymptomatic for at least 3 weeks,54 but other studies have shown timing of onset, peak, and 
resolution of shedding was similar for inoculated participants whether or not they developed 
clinical gastroenteritis.53 Because the highest period of infectivity is believed to coincide 
with clinical symptoms and the period shortly thereafter, the Centers for Disease Control and 
Prevention recommends excluding sick health care personnel, food workers, and caregivers 
for 48 hours to 72 hours after symptoms resolve.9
IMMUNITY
Immunity to norovirus is complex and an ongoing field of research; both acquired immunity 
and innate host factors and are thought to contribute to susceptibility to infection. Data from 
volunteer challenge studies indicate a pattern of short-term, acquired immunity, with 
protection against the same norovirus strain lasting for weeks up to 2 years.55–57 Modeling 
studies suggest a slightly longer duration of protection (4–9 years).58 As a result, immunity 
to norovirus is thought to be of limited duration, with most individuals experiencing several 
infections throughout their lifetime.
Antibodies from natural infection have been studied as possible markers of immunity. 
Antibody prevalence correlates with increasing age; 1 study of hospitalized patients with 
acute gastroenteritis demonstrated that infants had the lowest GII.4-specific IgG and IgA 
prevalence, increasing with age up to 100% prevalence in adults.59 Although antibody 
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seroprevalence to norovirus in adulthood is high, this does not necessarily correlate with 
protection from disease.55,60 At the same time, other studies have indicated high blocking 
ability of antibodies is correlated with protection against infection.61–63
Immunity to norovirus seems to be homotypic, with greater protection to strains within 
genogroups compared with between genogroups57,59 and could be one reason why high 
seroprevalence to norovirus does not necessarily equate with protection from disease. 
Challenge studies have indicated protection against homologous strains but lack of cross-
protection to heterologous strains.57 Even within a genogroup, protection might be 
incomplete; studies have shown that although repeat infections by the same genotype are 
rare, repeat infections by the same genogroup occur commonly.64,65
In addition to acquired immunity, innate host factors play an important role in immunologic 
protection. Intrinsic susceptibility to norovirus infection is mediated by histo-blood group 
antigens (HBGAs), including ABO, secretor, and Lewis types. HBGAs have been 
demonstrated to serve as a docking site or receptor for noroviruses and are believed to play a 
role in virus entry to the gut mucosal epithelial cells.62 The expression of HBGAs is 
regulated in part by the FUT2 gene, which encodes an alpha(1,2) fucosyltransferase to 
generate H-antigens, which are catalyzed to produce A or B blood group antigens. Those 
individuals who possess a functional FUT2 gene, which results in ABH glycans secreted 
into bodily fluids, are known as secretor-positive individuals and have been found to have a 
higher risk of norovirus infection.66 Conversely, individuals with polymorphisms in FUT2 
that can result in a homozygous nonsense mutation are known as nonsecretors; these 
mutations vary by ethnicity and occur in approximately 5% to 50% of different populations 
worldwide.67 Protection may not be complete, however, based on FUT2 status alone, 
because secretor-negative individuals can be infected with norovirus, with some 
demonstrated differences in susceptibility to certain genotypes.67–69
DIAGNOSIS
Individual cases of norovirus gastroenteritis can be suspected on the basis of clinical 
manifestations. Routine laboratory tests in affected individuals are generally nonspecific, 
although peripheral white blood cell counts can be slightly elevated with increased 
polymorphonuclear cells and relative lymphopenia.16 Renal and hepatic function is 
generally normal unless dehydration ensues.
Confirmation of norovirus as an infectious agent in patients requires laboratory testing of 
stool specimens. Whole-stool samples are the preferred clinical specimen for detection of 
norovirus and ideally are collected during the acute phase of illness, but norovirus can also 
be detected from rectal swabs and vomitus. Serum specimens are not recommended for 
routine diagnostics9; although several serologic markers, including norovirus-specific IgA 
and IgG titers, HBGA-blocking antibodies, and mucosal and fecal IgA, are being explored in 
the context of research and vaccine trials,10 correlates of protection for use in the clinical 
setting are still under development.
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Molecular tests, including conventional reverse transcription (RT)–polymerase chain 
reaction (PCR) and real-time RT-PCR are most sensitive and currently the gold standard for 
norovirus detection but are usually only available in public health laboratories and research 
facilities (Table 1). RT-quantitative (q)PCR afford several advantages, because it is the most 
sensitive assay available, can detect GI, GII, and GIV strains simultaneously and in several 
types of specimens (stool, vomitus, food, water, and environmental) and through use of an 
internal extraction control can reduce falsenegative results.70,71 It can also provide an 
estimate of viral load based on the cycle threshold value; some data suggest that patients 
with higher viral loads excrete virus longer.71 One consideration when using RT-qPCR is 
that norovirus is frequently detected in stool samples of healthy and asymptomatic 
individuals, which can complicate interpretation of results; however, detection of norovirus 
in asymptomatic controls seems more common in developing countries.72 Laboratory 
diagnostics in the clinical setting have only recently become more widely available. 
Molecular-based assays for multiple enteric pathogens, such as xTAG GPP (Luminex, 
Toronto, Canada), FilmArray gastrointestinal panel (BioFire Diagnostics, Salt Lake City, 
Utah), and Verigene Enteric Pathogens Test (Nanosphere, Northbrook, Illinois), can detect 
multiple viral, bacterial, and parasitic pathogens simultaneously within a few hours.71 The 
equipment and testing can be expensive, however, and interpretation of positive results with 
mixed infections can pose challenges for appropriate treatment and management of patients.
Other diagnostic tests include electron microscopy assays, enzyme immunoassay, and 
immunochromatographic lateral flow assays. Electron microscopy can detect multiple viral 
pathogens but is expensive and insensitive and generally only used in reference laboratories.
71
 Enzyme immunoassay and immunochromatographic assays are commercially available, 
allow for rapid results and have high specificity, but, because of large genetic and antigenic 
variation among noroviruses and variable viral loads in stool samples, they have low 
sensitivity (35%–76%) and are not recommended for individual patients.71,73–75 They can 
be useful, however, for rapid screening of multiple samples, such as in an outbreak setting.75 
Negative tests should still be confirmed by a second technique in an outbreak setting, such as 
RT-qPCR.
In an outbreak setting, and in situations where stool samples are not available for testing but 
rapid diagnosis is paramount, norovirus infections can be suspected based on the clinical and 
epidemiologic profile. The Kaplan criteria provide the means to discriminate between 
outbreaks due to norovirus and due to bacterial agents and include (1) vomiting in more than 
half of affected persons, (2) mean (or median) incubation period of 24 hours to 48 hours, (3) 
mean (or median) duration of illness of 12 hours to 60 hours, and (4) no bacterial pathogen 
in stool culture.76,77 These criteria are highly specific (99%) but less sensitive (68%) in 
discriminating between outbreaks due to bacteria versus norovirus.78 Other clinical and 
epidemiologic profiles have been suggested to help discriminate norovirus outbreaks from 
non-norovirus gastroenteritis outbreaks, including an increased vomiting to fever ratio and 
decreased diarrhea-to-vomiting ratio.79,80 These clinical definitions are of particular 
importance in nursing homes and assisted living facilities, where diagnostic testing might 
not be obtained and could lead to delays in diagnosis and implementation of control 
measures.
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TREATMENT
As with other causes of viral gastroenteritis, treatment is primarily supportive with 
replenishment of intravascular depletion of volume and electrolytes as well as unrestricted 
nutrition.13,16 Oral rehydration remains the first-line therapy for uncomplicated illness and 
intravenous fluids for severe vomiting and dehydration.15 Older adults with signs of 
hypovolemia are at greatest risk for complications and are more likely to require 
hospitalization. Symptomatic treatment with analgesics, antimotility, antiemetic, and 
antisecretory agents can be used as adjuncts in adults, depending on the type and severity of 
symptoms and necessity of continued performance, such as work and travel. One study 
demonstrated that bismuth salicylate improved symptoms from gastroenteritis in Norwalk 
virus–infected volunteers but had no effect on the number or consistency of stools or rates of 
viral shedding.81 A more recent study found that in vitro, bismuth subsalicylate and bismuth 
oxychloride slightly reduced the level of Norwalk replicon-bearing cells.82 Loperamide has 
been shown to reduce the duration of diarrhea from a variety of causes compared with 
placebo and has few side effects,83 although constipation was reported in 1 study in adults 
greater than 70 years old.84 In adults with diarrhea for less than 24 hours, diphenoxylate-
atropine [Lomotil] was superior to placebo in reducing the rate of bowel movements in the 
24 hours after treatment, but there was no statistically significant difference in median time 
to last loose or watery stool.85
Antibiotics are not recommended for the treatment of uncomplicated viral gastroenteritis, 
and no Food and Drug Administration–approved antiviral therapies are available for 
norovirus gastroenteritis, but research to identify antiviral treatment strategies for norovirus 
is in progress.86,87 Nitazoxanide, a broad-spectrum thiazolide anti-infective licensed for use 
against Cryptosporidium spp and Giardia lamblia, has been used off-label as a treatment of 
norovirus infection in transplant recipients and immunocompromised patients,88–90 and a 
small clinical trial demonstrated significant reductions in time to resolution of symptoms of 
norovirus diarrhea in immunocompetent adults and adolescents treated with nitazoxanide.91 
Other investigational agents, including the antiviral favipiravir, under development for 
influenza treatment, have shown modest potency against norovirus replication.92 Human 
alpha-interferon and ribavirin also reduced replication of a human norovirus replicon in cell 
culture.93 Probiotics and vitamin A are also being explored for their antiviral effects94; 
reductions in incidence and shorter duration of diarrhea and viral shedding have been 
demonstrated with probiotic regimens in pigs inoculated with human norovirus.95 Until 
recently, lack of a robust and reproducible in vitro cultivation system hampered research and 
development for therapeutics, but a human intestinal enteroid culture system has been 
described to support human norovirus replication in vitro96 and is expected to yield new 
insights for antivirals as well as in diagnostics and vaccine development.
ENDEMIC DISEASE
Studies of endemic norovirus gastroenteritis have elucidated some important trends. In the 
United States, norovirus is the leading cause of gastroenteritis in the community, outpatient 
setting, and emergency departments in all age groups, accounting for 19 million to 21 
million cases annually.1 Estimates of the total number of cases in adults greater than or equal 
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to 65 years of age in the United States have not previously been reported; extracting a 
recently reported community incidence rate in this age group and multiplying by the total 
number of persons greater than or equal to age 65 in 201597 results in an estimated 3.7 
million total cases of norovirus annually in the United States in older adults (Fig. 2). 
Additionally, norovirus cases in older adults account for an estimated 320,000 outpatient 
visits; 69,000 emergency department visits; 39,000 hospitalizations; and 960 deaths annually 
in the United States. These estimates are in line with a recent systematic review of older 
adults in HI/UMI countries, which reported 1.2 million to 4.8 million illnesses;723,000 
million to 2.2 million outpatient visits; 40,000 million to 763,000 inpatient visits; and 2000 
to 13,000 norovirus-associated deaths annually in these countries.3 Putting these counts 
together with the overall population of 402 million older adults in HI/UMI countries, 
norovirus incidence rates can be calculated for these countries, which are similar to 
incidence rates previously reported from the United States (total cases: 12 vs 77 per 1000; 
outpatient visits: 5.5 vs 5.4–7.9 per 1000; inpatient visits: 190 vs 81 per 100,000; deaths: and 
32 vs 20 per 1,000,000; rates are in HI/UMI vs United States, respectively). As the world 
population continues to grow and age, these numbers will correspondingly increase.
Studies from the United States, the United Kingdom, Canada, and Germany have reported 
age-specific norovirus incidence rates that have included adult populations (Table 2). 
Estimates vary by outcome, country, and estimation methods, but a U-shaped pattern of 
illness with the youngest and eldest most highly affected was evident among several studies 
that examined all age groups. For example, a study of patients submitting stool specimens 
for routine clinical diagnostics from a health maintenance organization in 2 regions of the 
United States reported highest incidence rates in children less than 5 years of age in the 
community (1521 per 10,000), followed by adults 46 years to 65 years of age (1012 per 
10,000) and greater than 65 years of age (771 per 10,000); similarly, children less than 5 
years of age had the highest outpatient incidence rate (256 per 10,000), followed by adults 
greater than 65 of age (79 per 10,000).98 Another US modeling study estimated norovirus 
associated hospitalization discharges that likewise followed the U-shaped distribution, with 
the oldest age groups most affected.4 When examining hospitalization, emergency 
department, and outpatient visit rates among adults only, higher incidence is observed 
among adults greater than 65 compared with adults less than or equal to 65 years old.4,99–105 
Among adults greater than 65 years, the hospitalization rate appears to be even greater with 
increasing age, because the greater than 84-year-old group exhibited rates at least twice as 
high.4,101 Unlike the studies discussed previously, 2 studies reported rates in adults that were 
much lower than the others (0.61 per 10,000 in >59 year olds and 0.0041 per 10,000 in 65–
85 year olds), but these were the only estimates that relied entirely on International 
Classification of Diseases, Ninth Revision, and International Classification of Diseases, 
Tenth Revision, codes, and the investigators noted that a substantial proportion of 
undiagnosed viral gastroenteritis cases were likely.103,106
Adults greater than or equal to 65 years of age are at highest risk for death from norovirus; a 
study in the Netherlands reported a case fatality rate 21 times higher in this age group 
compared with adults 18 years old to 64 years old.107 Among studies estimating the 
incidence of norovirus-associated mortality, death rates were much higher in older adults 
compared with other age groups (see Table 2). In 2012, Hall and colleagues35 reported a 
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death rate in adults greater than or equal to 65 that was 2 orders of magnitude higher than in 
children and adults 5 years to 64 years of age (0.2 vs 0.002 per 10,000, respectively) and in 
2013 Werber and colleagues105 reported a similarly high rate in older adults greater than or 
equal to 70 compared with less than 70 years of age (0.32 vs <0.01 per 10,000).
Prevalence studies in patients with acute gastroenteritis have also demonstrated a high 
burden of norovirus disease. Globally, noroviruses account for 18% of all patients with acute 
gastroenteritis, with slightly lower rates in the inpatient (17%) compared with outpatient 
(20%) and community (24%) setting.72 Studies from Canada, China, the Netherlands, 
Portugal, Spain, Qatar, the United States, and the United Kingdom have demonstrated that 
norovirus accounted for 6% to 27% of acute gastroenteritis cases in adults of all ages, and 
8% to 41% of acute gastroenteritis in adults greater than or equal to 65 years old (Table 3).
OUTBREAKS
Globally, norovirus is the predominant cause of gastroenteritis outbreaks and accounts for 
approximately half of all outbreaks in developed countries.122 In the United States, 
norovirus is also the leading cause of foodborne disease outbreaks123 and a frequent cause of 
outbreaks in institutional settings, such as LTCFs and child care centers.122 Other common 
norovirus outbreak settings include restaurants, catered events, cruise ships, schools, prisons, 
and military encampments.
These outbreaks occur year-round but are more frequent during the winter, with more than 
half occurring in the December-February timeframe.9,124 Although multiple routes of 
transmission can occur within a single outbreak, norovirus is the most frequently reported 
cause of acute gastroenteritis outbreaks transmitted through person-to-person contact, 
environmental contamination, and unknown mode of transmission.125 Most norovirus 
outbreaks globally and in the United States are caused by GII noroviruses, and GII.4 is the 
most common genotype identified in norovirus outbreaks in the United States.12,126
Long-term Care Facility Outbreaks
Older adults living in LTCFs might be at additional risk for norovirus infection and 
complications.127 In the United States, LTCFs, which generally refer to facilities that 
provide prolonged care for individuals who require daily living and/or nursing care support, 
are the most commonly reported setting for norovirus outbreaks.125,128,129 In the United 
States and Australia, 6 to 17 norovirus outbreaks per 100 LTCFs are estimated annually.
130,131
The unique setting of LTCFs can promote norovirus transmission, such as in shared rooms 
and common areas, where norovirus can spread through many routes, including person-to-
person contact, contact with contaminated surfaces, and airborne dissemination of vomitus.
132
 Most norovirus outbreaks in LTCF settings have high levels of person-to-person 
transmission, likely due to the caregiving and close contact required between staff and 
residents with limited mobility.130,131,133,134 Shared dining facilities in some LTCFs might 
also increase the risk for foodborne exposures and transmission.
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Attack rates and deaths are also higher in norovirus outbreaks in LTCF compared with other 
causes of acute gastroenteritis outbreaks.36,105,130,131,133 A systematic review of norovirus 
disease risk among older adults in HI/UMI countries found that attack rates ranged from 3% 
to 45%, case hospitalization rates 0.5% to 4.3%, and case fatality rates 0.3% to 1.6% in 
norovirus-associated LTCF outbreaks.3 Once infected, LTCF residents are more likely to 
suffer severe outcomes due to nutritional status, immunosenescence, chronic inflammation, 
microbiome alterations, and use of certain medications.135 Outbreaks in LTCFs have been 
reported to recur within the same facility despite implementation of control measures; can 
last for prolonged periods, up to months in some cases136; and result in increased 
hospitalizations and mortality rates for residents.36,125
Hospital Outbreaks
Norovirus outbreaks are common in hospitals, with attack rates ranging from 5% to 60%.
31,108,133,137,138
 These outbreaks tend to occur seasonally, more commonly occurring in the 
6 months from November to April and peaking in January, February, and March.108,133 
Transmission is most likely to be person to person, and the outbreak length can range from 1 
day to months.133 Hospital outbreaks are more commonly reported from several developed 
countries, at times leading to closure of wards or hospitals compared with the United States, 
where outbreaks in LTCFs predominate.9,137–141 The reason for these differences in 
norovirus hospital outbreak setting and control measures by country is not well understood 
but could be due to differences in reporting, testing, infection control, or epidemiology.
142,143
Few studies have examined norovirus genotypes affecting older adults, but available 
evidence suggests that GII.4 viruses predominate as a cause of norovirus disease in both 
LTCFs and health care–associated outbreaks as well as among older adults hospitalized for 
acute gastroenteritis.32,101,135 GII.4 outbreaks have been associated with more severe illness, 
hospitalizations, and deaths.10,11,144
PREVENTION AND CONTROL OF NOROVIRUS OUTBREAKS IN HEALTH 
CARE SETTINGS
Health care facilities, including LTCFs and hospitals, are the most commonly reported 
settings for norovirus outbreaks in the United States and other industrialized countries.9 
These outbreaks pose risks to patients, health care personnel, facility staff, and visitors and 
can affect the provision of care extending beyond an affected ward or unit.
Patient Cohorting and Isolation Precautions
In health care settings where the risk of transmission is high, transmission-based precautions 
can be the most effective means of interrupting transmission. Patients with symptoms of 
norovirus gastroenteritis should be separated from asymptomatic patients, and placed in a 
single occupancy room whenever possible.77 In absence of available private rooms, facilities 
should cohort symptomatic patients to reduce ongoing transmission. The patients should be 
managed with standard and contact precautions. Contact precautions should be maintained 
until at least 48 hours after resolution of symptoms; longer periods of time can be considered 
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for those with complex medical problems who may experience prolonged diarrhea, viral 
shedding, and symptom relapse. Patient movement within a ward or unit should be 
minimized, and symptomatic and recovering patients should not leave the patient care area 
unless it is medically necessary. Nonessential visitors should be restricted from affected 
areas.77
Staff Precautions, Hand Hygiene, and Personal Protective Equipment
Ill staff members should be excluded during their illness and for 48 hours to 72 hours after 
symptom resolution.77 To minimize the spread of infection, staff who have worked on 
affected areas should not be transferred to or work on unaffected areas for 48 hours after 
exposure.9 Nonessential staff should be excluded from working in areas experiencing a 
norovirus outbreak.
During outbreaks, washing hands with plain or antiseptic soap and running water for 20 
seconds is paramount before and after providing care for patients with suspected or 
confirmed norovirus gastroenteritis. The use of alcohol-based hand sanitizers might 
additionally provide protection in between handwashing; however, studies have shown 
mixed effectiveness of alcohol-based hand sanitizers against norovirus and their use for 
norovirus remains controversial.9
Personal protective equipment with contact and standard precautions (ie, gown and gloves) 
is recommended for persons entering the patient care area.77 If there are anticipated risks of 
splashing to the face, such as with patients who are vomiting, use of a surgical or procedure 
mask and eye protection or a full face shield can be considered.
Patient Transfer and Ward Closure
Consideration to the closure of wards to new admissions or transfers should be given to help 
reduce the size of the outbreak. Individuals recovering from symptoms can be discharged to 
their residence. Ward closure can be a costly measure and disruptive to the provision of care; 
the threshold for ward closure depends on the size of the outbreak and risk assessments by 
infection control personnel and facility leadership.2,77
Environmental Cleaning
Routine cleaning and disinfection of frequently touched environmental surfaces are key to 
interrupting norovirus spread; high-contact areas include toilets, faucets, hand/bed railings, 
phones, door handles, computer equipment, and kitchen preparation surfaces. In health care 
settings, Environmental and Protection Agency–registered products with label claims for use 
in health care settings should be used according to manufacturer’s recommendations (https://
www.epa.gov/pesticide-registration/list-g-epa-registered-hospital-disinfectants-effective-
against-norovirus). Sodium hypochlorite (chlorine bleach) is the preferred agent to disinfect 
human norovirus from surfaces and should be applied at a concentration of 1000 ppm to 
5000 ppm (5–25 tablespoons household bleach per gallon of water).9
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VACCINE PROSPECTS
A norovirus vaccine has the potential to reap enormous benefits to society, through reduction 
in morbidity and mortality as well as cost savings. In the United States, vaccination could 
avert 1.0 million to 2.2 million cases annually, assuming 50% efficacy and 12 months of 
protection; a vaccine with longer duration of protection up to 48 months and 75% efficacy at 
a cost of $50 could prevent 21,000 to 47,000 hospitalizations and 240 to 550 deaths and save 
$100 million to $2.1 billion dollars annually.145 Norovirus vaccines in development have 
been based on virus-like particles (VLPs), which contain the major capsid antigen but lack 
genetic material for viral replication.146 VLPs have been shown to be morphologically and 
antigenically similar to native viruses and cause humoral, mucosal, and cellular immune 
responses after oral and intranasal administration.147–149
There are several norovirus vaccines that are under development in preclinical and clinical 
trials using VLPs and involving intranasal, oral, and intramuscular routes of administration. 
One of the earlier candidates was a monovalent intranasal GI.1 VLP vaccine that 
demonstrated a serologic response in 70% of healthy adults who received 2 doses of the 
vaccine.150 This candidate vaccine was also efficacious against homologous challenge, and 
reduced the risk of gastroenteritis by 47% (95% CI, 15%-67%) and infection by 26% 
(95%CI, 1%-45%) and was well tolerated and immunogenic.150 The vaccine was 
subsequently modified from an intranasal to an intramuscular route of administration and 
from a monovalent to a bivalent formulation. It is currently in phase II clinical trials, 
contains GI.1 and GII.4 VLPs, and is the vaccine furthest along in clinical development.151 
Serologic responses were demonstrated for both GI.1 and GII.4 as well as protection against 
severe clinical symptoms; however, vaccine efficacy was only 13.6% (95%CI, 
−21.0%-38.3%) for human norovirus infection. The only other vaccine in clinical trials is an 
adenoviral-vector based vaccine in a tablet formulation that encodes for a full length VP1 
gene from GI.1; this vaccine recently met primary and secondary endpoints for safety and 
immunogenicity in an adult population in a phase I trial.152
Because norovirus affects multiple age groups, and unique populations have specific risk 
factors, including travelers, health care workers, individuals in LTCFs, and food handlers, 
developing a research agenda and clinical development plan has been challenging. The 
vaccine candidates discussed previously have been studied in healthy adults, but the greatest 
burden of disease is in young children and older adults, and a vaccine is likely to yield 
greatest impact in these age groups.145 Ongoing clinical trials in these groups include the 
intramuscular GI.1/GII.4 vaccine candidate with aluminum hydroxide adjuvant in the 
pediatric population as well as safety and immunogenicity studies of the bivalent 
formulation in adult and elderly participants.153
Several considerations remain for the development of a norovirus vaccine. First, due to 
limited duration of immunity after natural infection and challenge studies, as well as the 
continual emergence of new strains, any vaccine candidate will warrant close attention to the 
duration of protection, need for booster doses, and reformulation. Second, the diversity 
between and within genogroups will necessitate development of a vaccine that affords broad 
heterotypic protection; a multivalent vaccine could offer such protection.154 Third, given 
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prior exposure and underlying conditions, the immune response is likely to differ in children, 
adults, the elderly, and the immunocompromised; consideration of different vaccines for 
these populations might be explored. Fourth, uptake of vaccines in the elderly has proved 
challenging. Incorporation into the childhood immunization schedule might be more feasible 
and could have important indirect benefits by limiting transmission in the general 
population, but the complexity of the pediatric schedule necessitates careful consideration of 
many factors, including acceptability and level of vaccine effectiveness. Combination 
vaccines could improve acceptability across different age groups; products in the preclinical 
phase include a trivalent norovirus/rotavirus combination vaccine, and a norovirus P particle 
dual vaccine that includes norovirus with influenza, hepatitis E, and rotavirus.10 
Additionally, targeting high-risk groups for vaccine receipt, such as vaccination of older 
adults who are living in LTCFs as well as staff and employees who work there, could be an 
attractive option for this particularly vulnerable population.
SUMMARY
The burden of norovirus disease is vast, and older adults are particularly at risk for severe 
outcomes, including prolonged symptoms and death. LTCFs and hospitals are the most 
commonly reported settings for norovirus outbreaks in developed countries, and older adults 
in these settings are more likely to experience health care–associated infection with more 
severe infections and poor outcomes. Although the current treatment of norovirus infection 
is primarily supportive, with the recent description of a human enteroid culture system, 
renewed interest in development of antivirals is anticipated. In addition, the future holds 
promise for prevention of disease, because several norovirus vaccines in clinical trials have 
the potential to reap enormous benefits for multiple age groups and populations.
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KEY POINTS
• Estimates indicate that a vast majority (90%) of norovirus-associated deaths 
in the United States occur among persons greater than or equal to 65 years of 
age.
• In the United States, long-term care facilities are the most commonly reported 
setting for norovirus outbreaks.
• Norovirus can spread through many routes, including person-to-person 
contact, contact with contaminated surfaces, and airborne dissemination of 
vomitus.
• Transmission-based precautions are among the most effective means of 
interrupting transmission.
• Antiviral therapy is not yet available for norovirus gastroenteritis, but research 
to identify antiviral treatment strategies for norovirus is in progress.
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Fig. 1. 
Proportion of annual norovirus burden in the United States that occurs in older adults greater 
than or equal to 65 years old, by outcome. aHall and colleagues,35 2012; bLopman and 
colleagues,4 2011; cGastañaduy and colleagues,5 2013; and dGrytdal and colleagues,102 
2015.
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Fig. 2. 
Estimated annual norovirus cases in older adults (≥65 years old) in the United States in 
2015, by outcome. To generate case counts, incidence rates by outcome were obtained or 
calculated from existing literature (aHall and colleagues,35 2012; bLopman and colleagues,4 
2011; cGastañaduy and colleagues,5 2013; and dGrytdal and colleagues,102 2015) and 
multiplied by the US population estimate for older adults in 2015 (47.8 million). For deaths 
and emergency department visits, 95% CIs are shown in parentheses; for outpatient visits, 
the average from 2 studies is shown; for hospitalizations, high and low seasonal estimates 
from 1996 to 2007 are shown; for total illnesses, 95% credible intervals are shown. All 
numbers are rounded to 2 significant digits. Data collected at the community level are used 
as proxy for determining total illnesses.
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